about
Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxideAsymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosisStatins as regulators of redox state in the vascular endothelium: beyond lipid loweringAsymmetric Dimethylarginine Is a Well Established Mediating Risk Factor for Cardiovascular Morbidity and Mortality-Should Patients with Elevated Levels Be Supplemented with Citrulline?Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General PopulationmiR-21/DDAH1 pathway regulates pulmonary vascular responses to hypoxia.An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype.Vaspin increases nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells.Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes.Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2.Dimethylarginine dimethylaminohydrolase II overexpression attenuates LPS-mediated lung leak in acute lung injury.Cerebral changes occurring in arginase and dimethylarginine dimethylaminohydrolase (DDAH) in a rat model of sleeping sicknessMechanisms of nitric oxide synthase uncoupling in endotoxin-induced acute lung injury: role of asymmetric dimethylarginine.Proteome changes of lungs artificially infected with H-PRRSV and N-PRRSV by two-dimensional fluorescence difference gel electrophoresis.Optimization of the separation of NDA-derivatized methylarginines by capillary and microchip electrophoresis.Pilot study of the association of the DDAH2 -449G polymorphism with asymmetric dimethylarginine and hemodynamic shock in pediatric sepsis.Identification of small-molecule enhancers of arginine methylation catalyzed by coactivator-associated arginine methyltransferase 1.The Role of Obesity in Preeclampsia.Alterations in energy metabolism, neuroprotection and visual signal transduction in the retina of Parkinsonian, MPTP-treated monkeysEndothelium-dependent contractions in hypertension.Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic miceActivity-based protein profiling of protein arginine methyltransferase 1.Arginine metabolic endotypes in pulmonary arterial hypertension.Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study.Protein interfaces in signaling regulated by arginine methylation.Evaluation of asymmetric dimethylarginine, arginine, and carnitine metabolism in pediatric sepsis.Arginine increases development of in vitro-produced porcine embryos and affects the protein arginine methyltransferase-dimethylarginine dimethylaminohydrolase-nitric oxide axis.Liver proteomics for therapeutic drug discovery: inhibition of the cyclophilin receptor CD147 attenuates sepsis-induced acute renal failureGenome-wide association study of L-arginine and dimethylarginines reveals novel metabolic pathway for symmetric dimethylarginine.Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy.Arginine and nitric oxide pathways in obesity-associated asthma.Determination of the diagnostic values of asymmetric dimethylarginine as an indicator for evaluation of the endothelial dysfunction in patients with rheumatoid arthritisThe chemical biology of nitric oxide: implications in cellular signalingHeat-assisted extraction for the determination of methylarginines in serum by CE.ADMA injures the glomerular filtration barrier: role of nitric oxide and superoxide.Asymmetric dimethylarginine inhibits HSP90 activity in pulmonary arterial endothelial cells: role of mitochondrial dysfunctionDimethylarginine Dimethylaminohydrolase 2 (DDAH 2) Gene Polymorphism, Asymmetric Dimethylarginine (ADMA) Concentrations, and Risk of Coronary Artery Disease: A Case-Control Study.The transporter and permeability interactions of asymmetric dimethylarginine (ADMA) and L-arginine with the human blood-brain barrier in vitro.Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease.FXR an emerging therapeutic target for the treatment of atherosclerosis
P2860
Q24321779-65D6533B-1AB0-4F9B-8ACE-125D982F92DBQ26795604-4ABC1CFA-616F-40C2-A832-36EBB7DE3C4AQ26853120-D970D643-4B72-4ED8-8F8F-B405E62AAA65Q28075206-700AEF3A-4285-45A1-8C69-B8CFC5D8B26EQ28548045-2A7A589D-1938-4807-8378-2BF91A341216Q29871524-AB67F69B-CB44-4075-A7B7-4BDB2AECF94CQ30415302-25A0EA43-9558-4A0A-A241-7EEC9A94A14EQ31110218-D173E73D-4FF5-40B8-A74A-471EF01645B2Q33538038-BF8F44DC-70AA-40B1-9B70-733A30482708Q33589158-E5A43C8C-BAB5-4B65-BE8A-B5CDC83203BEQ33799650-FFAE0C31-865C-44D5-8412-CC536BC424E7Q33847194-858106F8-E8FE-4A81-9B24-8E95733DFCBDQ33889586-4EE8F8D1-DD7A-448E-ACD6-0E2AF1E6B87EQ33920099-2DC44FA1-81A5-4BFC-974E-0E1D7F57DE15Q34167247-3A67394D-7AC4-4EDB-8953-7D444441E839Q34200808-BDCCF47F-5C24-42A8-AD62-DE81266B1972Q34456824-F8A07296-C723-46F0-B762-5C63246254A9Q34853745-5198047C-C8BB-4892-8EC5-19C415E667FFQ34990005-1440AB45-C10B-4725-8A23-9F7D2073FB3BQ35048636-835EEE38-EE71-4580-B20A-A2D914036F75Q35153847-A4C9829E-E2E3-426A-A75F-8125EDBFF76EQ35420805-08CB3D9C-0171-4D1D-B422-17D214B17D81Q35517452-B147628B-1998-4F3C-9D84-5410557C4485Q35544768-74A15106-7275-4116-94D9-F02CCB744A0BQ36043261-D5F7735C-CFCB-42B7-9993-64701D3D00C6Q36083890-6013AB47-242B-45B8-8F37-D275D5E95221Q36501368-7EFBF7E9-7C60-4F5A-8CF5-70C87115A467Q36515910-119D788C-11E0-4E0B-998C-3B4B40D47717Q36701882-06EAF92D-38C5-4449-95C0-5BF93B82FABBQ36810804-31EF7791-1A01-4580-BB10-2E5D98359459Q36845120-3F13CD70-9223-4AD8-8DEA-77AE2D864444Q36898455-FC4697E8-DEEA-4F51-8415-72C9E05D8351Q36948369-20F459A9-23D4-460F-B3BC-2AD5D8F7E1A6Q37096680-A0FD4D82-6AFF-4FB5-B891-9C93E82A9043Q37216894-24969FA9-C0A9-4C06-8AB9-F35BC6BAFA83Q37274252-158F73DD-6E2C-4082-8509-834FDAF42E16Q37290635-B91F061A-B3D2-4C71-8808-2C5479FFA489Q37296720-F6EE4578-1210-43EC-9892-681C7DE764EAQ37324434-E1FBCB59-D301-461C-ADE0-48176E3C1DF8Q37334984-BED07B82-D518-4898-8F0B-659B7CC6EFC7
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The DDAH/ADMA/NOS pathway.
@ast
The DDAH/ADMA/NOS pathway.
@en
type
label
The DDAH/ADMA/NOS pathway.
@ast
The DDAH/ADMA/NOS pathway.
@en
prefLabel
The DDAH/ADMA/NOS pathway.
@ast
The DDAH/ADMA/NOS pathway.
@en
P2093
P1476
The DDAH/ADMA/NOS pathway.
@en
P2093
Cam T L Tran
James M Leiper
Patrick Vallance
P356
10.1016/S1567-5688(03)00032-1
P577
2003-12-01T00:00:00Z